resolutions on the important agenda of the Board of Directors Meeting of the Company No. 5/2017, held on 7 November 2017, as follows: 1. Resolved for approval of the submission to the Shareholders’ meeting for
Exchange Commission hereby issues the following regulations: Clause 1. The Notification of the Office of the Securities and Exchange Commission No. Sor Nor. 34/2549, Re: Additional Rules for Approval of Fund
, Re: Additional Rules for Approval of Fund Manager dated 30 August 2006 shall be repealed. Clause 2. In this Notification: “Executive Director” means any person who is appointed by the board of
persons ) and related services i.e. registration with Food and Drug Administration (FDA), trademark permission, product and packaging design, and brand building etc. to customers who are business operator
transferred on share sale and purchase date from the seller’s connected persons ) and related services i.e. registration with Food and Drug Administration (FDA), trademark permission, product and packaging
. registration with Food and Drug Administration (FDA), trademark permission, product and packaging design, and brand building etc. to customers who are business operator in skin cares and cosmetics. In addition
international sales declined dramatically at 46.03% compared to the same period of the previous year. One of the issues was the delayed product delivery after the license was issued from China Food and Drug
granted a license from China Food and Drug Administration (CFDA) during the beginning of 2018 as the Company had to redesign and adjust product packaging according to the granted license as well as change